Atorvastatin Reactions 1680, p61 - 2 Dec 2017 Statin-associated autoimmune myopathy: case report A 70-year-old man developed statin-associated autoimmune myopathy following treatment with atorvastatin [route and indication not stated]. The man, who sustained a fall at home, was hospitalised to the ICU with large subdural haematoma. He was provided with respiratory support by mechanical ventilation. Before the fall, he had observed elevating pain and weakness positioned bilaterally in the hip girdle region and proximal shoulder. For the past two years, he had been receiving atorvastatin 40mg once daily and aspirin. On presentation, his creatine kinase (CK) level was 12300 IU/L. Atorvastatin was discontinued. In spite of this, the CK continued to be elevated, and there was no improvement in his clinical condition. Needle electromyography findings were suggestive of an active myopathic process with abnormal spontaneous activity. A muscle biopsy demonstrated pausi- immune necrotizing myopathy without any macrophage infiltration,vascular abnormalities and inclusion bodies. Serological testing demonstrated HMG CoA reductase autoantibodies suggestive of an autoimmune process. Based on the clinical and laboratory findings, a diagnosis of statin- associated autoimmune myopathy was made. He was treated with methylprednisolone and rituximab. Although, he continued to be on mechanical ventilation and sedation, improvement was seen in his CK level. Following a mild clinical improvement, he was taken off the ventilator. However, he developed a respiratory distress and underwent a tracheostomy followed by ventilation. Two months after his initial presentation, he was discharged on high dose corticosteroids, rituximab and methotrexate. However, he died three months later due to ventilator-associated pneumonia Author comment: "Herein, we examine a rare but serious case of statin-associated autoimmune myopathy (SAM)." Sweidan AJ, et al. A Case of Statin-Associated Autoimmune Myopathy. Clinical Medicine Insights: Case Reports 10: 1-4, 2017. Available from: URL: http:// - USA 803283971 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial